Compare APPF & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APPF | RYTM |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.8B |
| IPO Year | 2015 | 2017 |
| Metric | APPF | RYTM |
|---|---|---|
| Price | $148.25 | $107.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | ★ $286.78 | $131.14 |
| AVG Volume (30 Days) | 380.6K | ★ 765.9K |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $950,822,000.00 | N/A |
| Revenue This Year | $19.69 | $55.34 |
| Revenue Next Year | $16.70 | $86.06 |
| P/E Ratio | $124.20 | ★ N/A |
| Revenue Growth | ★ 19.72 | N/A |
| 52 Week Low | $142.56 | $62.29 |
| 52 Week High | $325.90 | $122.20 |
| Indicator | APPF | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 40.87 | 74.97 |
| Support Level | $145.78 | $97.65 |
| Resistance Level | $168.43 | $113.03 |
| Average True Range (ATR) | 7.81 | 4.92 |
| MACD | -2.07 | 2.17 |
| Stochastic Oscillator | 18.47 | 84.20 |
AppFolio Inc provides cloud-based software solutions for the real estate industry. Its property management software offers property managers an end-to-end solution to their business needs. The group's products include cloud-based property management software (Appfolio Property Manager). Its solutions are AppFolio Property Manager Core, AppFolio Property Manager Plus, and AppFolio Property Manager Max. It also offers value-added services, such as screening, risk mitigation, and electronic payment services. Its markets are Single-Family, Multifamily, Student Housing, Affordable Housing, Community Associations, Commercial, and Investment Management. The business activity of the firm predominantly functions in the United States and it generates revenue in the form of subscription fees.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.